<DOC>
	<DOCNO>NCT01202565</DOCNO>
	<brief_summary>There clearly need data efficacy biologic agent treatment nail scalp psoriasis , especially routine clinical setting . A case report find , publish data exists non-interventional study , post-marketing observational study ( PMOS ) reflect routine clinical practice . The aim PMOS evaluate long-term ( 12-month ) efficacy adalimumab treatment nail scalp psoriatic lesion routine dermatologic practice .</brief_summary>
	<brief_title>Effectiveness Adalimumab ( HUMIRA® ) Treatment Scalp Nail Affection Patients With Moderate Severe Plaque Psoriasis Routine Clinical Practice</brief_title>
	<detailed_description>This post-marketing observational study ( PMOS ) HUMIRA® prescribe usual manner accordance term local marketing authorization regard dose , population indication , follow local prescription and/or reimbursement guidance . Follow-up visit strictly schedule , rather leave judgment investigator within 12-month study period participant . Five visit indicate within 12-month observational period : Baseline follow-up 3 month , 6 month , 9 month 12 month ( Study End ) . As nail include general measure disease severity ( Psoriasis Area Severity Index [ PASI ] ) , Nail Psoriasis Severity Index ( NAPSI ) use assign score nail psoriasis . The scalp , though involved general measure disease severity ( e.g . PASI ) , represent 4-5 % body surface therefore poorly represent . Psoriasis Scalp Severity Index ( PSSI ) use quantify intensity scalp psoriasis change study . The association general skin localize nail scalp , change quality life response adalimumab therapy also examine .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients enrol PMOS fulfill criterion : 1 . Patients moderate severe plaque psoriasis eligible Humira therapy accord local product label prescription/reimbursement guideline 2 . Have significant psoriatic nail affection ( total Nail Psoriasis Severity Index NAPSI score hand foot ≥ 10 ) and/or significant psoriatic scalp affection ( Psoriasis Scalp Severity Index PSSI score ≥ 10 ) 3 . Adult ( ≥18 year age ) 4 . Have negative result tuberculosis ( TB ) screen test TB prophylaxis per local guideline 5 . Willing provide inform consent request local law regulation Patients fulfil exclusion criterion eligible PMOS : 1 . Meet contraindication outline late version local Summary Product Characteristics ( SmPC ) 2 . Participate another clinical/observational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Post-marketing observational study ( PMOS ) Protocol</keyword>
	<keyword>Moderate Severe Plaque Psoriasis</keyword>
	<keyword>Treatment Scalp Nail Affection</keyword>
	<keyword>Effectiveness Adalimumab ( HUMIRA® )</keyword>
</DOC>